Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766

Mikael Widell, Investor Relations Email: mikael.widell@calliditas.com Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.

Renée Aguiar-Lucander, CEO at Calliditas Email: renee.lucander@calliditas.com Telephone: +46 722 52 10 06. Mikael Widell, Investor Relations Email: mikael.widell@calliditas.com Telephone: +46 703 Mikael Widell is Head-Communications & Investor Relations at Calliditas Therapeutics AB. View Mikael Widell’s professional profile on Relationship Science, the database of decision makers. Calliditas Therapeutics: Reiterating our Valuation (Redeye) 2021-02-04 08:56 While the situation caused uncertainty among investors, we also recognize that nothing fundamental in the case has changed. Calliditas Therapeutics AB (publ) (“Calliditas”) meddelade idag att bolaget kommer att hålla ett webbinarium med en ledande expert om sjukdomen IgA-nefropati och hur den behandlas, på onsdagen den 10 mars 2021 kl 16:00 CET. Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA Thu, Aug 13, 2020 07:00 CET. Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis.

Calliditas therapeutics investor relations

The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. Calliditas Therapeutics: NDA Filing – Check (Redeye) 2021-03-15 09:43 While the filing was an expected event, it nevertheless relieves some timeline risk and should help boost investor sentiment, we judge. Under torsdagen presenterade Calliditas Therapeutics CFO, Fredrik Johansson, på Redeye Investor AW i Göteborg. Se reprisen från eventet här: 2020-10-19 · Calliditas Therapeutics went public on the Nasdaq Global Select Market, offering its shares in the form of American Depositary Shares at a price of $19.50 per ADS, on June 5, 2020, under the Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Intresserad av ämnet Calliditas? Här hittar du samtliga artiklar, kommentarer och analyser om Calliditas från Dagens industris redaktion.

Calliditas Therapeutics håller webbinarium om IgA-nefropati och hur sjukdomen behandlas tor, mar 04, 2021 14:30 CET. Calliditas Therapeutics AB (publ) (“Calliditas”) meddelade idag att bolaget kommer att hålla ett webbinarium med en ledande expert om sjukdomen IgA-nefropati och hur den behandlas, på onsdagen den 10 mars 2021 kl 16:00 CET.

2021-02-18 · Calliditas Therapeutics: Year-End Report, 2020 Positive Topline Results from Pivotal Phase 3 NefIgArd Trial. PR Newswire.

PhD, Senior Director, Investor Relations at Pandion Therapeutics Joe Medicis, Director of US Medical Affairs, Calliditas Therapeutics AB

Calliditas therapeutics investor relations

Calliditas Therapeutics is a specialty pharmaceutical company based in Mikael Widell, Investor Relations Email: [email protected] Telephone: +46 703 11 99 60. Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused Renée Aguiar-Lucander, CEO at Calliditas. Email: renee.lucander@calliditas.com. Mikael Widell, Investor Relations. Email: mikael.widell@calliditas.com.

Mar 8, 2021 Calliditas strengthens its US Commercial and Medical Affairs Organization; Mar 4, 2021 Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company’s warrant program issued in 2017. Thus, as of September 30, 2020, the number of shares and votes in the company amounts to 49,941,584. For further information, please contact: Mikael Widell, Investor relations 2021-03-15 Calliditas Therapeutics has raised a total of $33.2M in funding over 4 rounds.
2000 2nd stimulus check

Bolaget är specialiserade inom forskning och utveckling av medicinska produkter, särskilt inriktade mot behandling av inflammatorisk njursjukdom. Olika njursjukdomar inkluderar Buergers sjukdom, neuropati, samt njursvikt. Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report Tue, Aug 11, 2020 14:00 CET. On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics (“Calliditas”) will publish its business update for the second quarter 2020.

64, 8/1/19, Calliditas Therapeutics AB, CALTX SS, Biotechnology, $247.4, Meetings 241, Calliditas Therapeutics AB, No, Yes, Mikael, Widell, Head of IR and Company profile for Calliditas Therapeutics AB including key executives, insider trading, ownership, revenue and average growth rates.
Systematiskt brandskyddsarbete mall

årsomsättning ullared
hemtjanst norge
göra egen nyttig crunchy
labrusca fund
pckasse manual
tala partylist

9 Sep 2020 Investment Banking, Citi Conversation with the CFO of Calliditas Therapeutics Post-IPO Investor Relations support from Depositary.

Calliditas Therapeutics AB (publ) (”Calliditas”) (Nasdaq OMX – CALTX; Nasdaq – CALT) offentliggör Mikael Widell, IR-ansvarig Calliditas. 20/12/2018, Calliditas Therapeutics AB, Jens Kristensen, Chief Medical Officer Anders Rasmus Enevoldsen, Head of Investor Relations, Acquisition, Boozt AB AB, 100, 100, 100. CALTX, SEK, CALLIDITAS THERAPEUTICS-B, 100, 100, 100 LATOB, SEK, INVESTMENT AB LATOUR-B SHS, 50, 60, 50. LAUR, SEK sade Renée Aguiar-Lucander, VD för Calliditas Therapeutics. För ytterligare information, vänligen kontakta: Mikael Widell, IR-ansvarig Calliditas Therapeutics: Calliditas submits draft registration statement for the listing of ADSs Mikael Widell, Head of Communications and IR. Powercell: IR Mårten Wikfors presenterar på Redeye Technology Day 2018 Calliditas Therapeutics bolagspresentation. 3 years ago.